Your browser doesn't support javascript.
loading
Research progress of Claudin-low breast cancer.
Pan, Chenglong; Xu, Anqi; Ma, Xiaoling; Yao, Yanfei; Zhao, Youmei; Wang, Chunyan; Chen, Ceshi.
Afiliação
  • Pan C; Department of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
  • Xu A; Kunming Medical University, Kunming, Yunnan, China.
  • Ma X; Kunming Medical University, Kunming, Yunnan, China.
  • Yao Y; Department of Anesthesia, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
  • Zhao Y; Department of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
  • Wang C; Kunming Medical University, Kunming, Yunnan, China.
  • Chen C; Department of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Front Oncol ; 13: 1226118, 2023.
Article em En | MEDLINE | ID: mdl-37904877
Claudin-low breast cancer (CLBC) is a subgroup of breast cancer discovered at the molecular level in 2007. Claudin is one of the primary proteins that make up tight junctions, and it plays crucial roles in anti-inflammatory and antitumor responses as well as the maintenance of water and electrolyte balance. Decreased expression of claudin results in the disruption of tight junction structures and the activation of downstream signaling pathways, which can lead to tumor formation. The origin of Claudin-low breast cancer is still in dispute. Claudin-low breast cancer is characterized by low expression of Claudin3, 4, 7, E-cadherin, and HER2 and high expression of Vimentin, Snai 1/2, Twist 1/2, Zeb 1/2, and ALDH1, as well as stem cell characteristics. The clinical onset of claudin-low breast cancer is at menopause age, and its histological grade is higher. This subtype of breast cancer is more likely to spread to lymph nodes than other subtypes. Claudin-low breast cancer is frequently accompanied by increased invasiveness and a poor prognosis. According to a clinical retrospective analysis, claudin-low breast cancer can achieve low pathological complete remission. At present, although several therapeutic targets of claudin-low breast cancer have been identified, the effective treatment remains in basic research stages, and no animal studies or clinical trials have been designed. The origin, molecular biological characteristics, pathological characteristics, treatment, and prognosis of CLBC are extensively discussed in this article. This will contribute to a comprehensive understanding of CLBC and serve as the foundation for the individualization of breast cancer treatment.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Suíça